Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Apr 03 04:00PM ET
1.99
Dollar change
+0.61
Percentage change
44.20
%
Index- P/E- EPS (ttm)-452.26 Insider Own0.01% Shs Outstand1.46M Perf Week59.20%
Market Cap2.90M Forward P/E- EPS next Y-14.49 Insider Trans0.00% Shs Float1.46M Perf Month-28.16%
Income-24.13M PEG- EPS next Q-4.21 Inst Own3.33% Short Float8.26% Perf Quarter-53.83%
Sales0.00M P/S- EPS this Y81.87% Inst Trans26.57% Short Ratio0.23 Perf Half Y-68.00%
Book/sh3.26 P/B0.61 EPS next Y8.52% ROA-119.36% Short Interest0.12M Perf Year-98.65%
Cash/sh5.98 P/C0.33 EPS next 5Y51.40% ROE-284.28% 52W Range0.94 - 180.19 Perf YTD-53.83%
Dividend Est.- P/FCF- EPS past 5Y80.96% ROI-257.14% 52W High-98.90% Beta5.99
Dividend TTM- Quick Ratio1.72 Sales past 5Y2.12% Gross Margin- 52W Low111.19% ATR (14)0.53
Dividend Ex-Date- Current Ratio1.72 EPS Y/Y TTM83.04% Oper. Margin- RSI (14)44.90 Volatility78.86% 27.99%
Employees42 Debt/Eq0.97 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price21.00
Option/ShortNo / No LT Debt/Eq0.97 EPS Q/Q99.12% Payout- Rel Volume148.15 Prev Close1.38
Sales Surprise- EPS Surprise-15.35% Sales Q/Q- EarningsFeb 14 BMO Avg Volume514.96K Price1.99
SMA20-3.86% SMA50-35.58% SMA200-76.81% Trades Volume76,289,383 Change44.20%
Date Action Analyst Rating Change Price Target Change
Nov-05-18Initiated Ladenburg Thalmann Buy
Oct-05-17Resumed Piper Jaffray Overweight $6
Today 08:50AM
Mar-20-25 02:26PM
08:35AM
Mar-18-25 08:05AM
Mar-06-25 08:00AM
06:59PM Loading…
Feb-15-25 06:59PM
Feb-14-25 08:05AM
Jan-15-25 08:00AM
Dec-12-24 12:50PM
09:00AM
Dec-04-24 08:35AM
Nov-29-24 09:55AM
Nov-26-24 08:35AM
Nov-22-24 08:35AM
Nov-20-24 08:35AM
08:15AM Loading…
Nov-11-24 08:15AM
Nov-07-24 08:05AM
Oct-29-24 08:05AM
Sep-18-24 04:05PM
Sep-16-24 08:05PM
08:20AM
08:05AM
Sep-13-24 08:20AM
08:05AM
Aug-13-24 08:05AM
Aug-08-24 08:05AM
Jul-01-24 04:20PM
Jun-28-24 09:20AM
Jun-17-24 07:40AM
Jun-03-24 08:05AM
08:05AM Loading…
May-14-24 08:05AM
May-08-24 12:54PM
08:05AM
May-02-24 07:37AM
Apr-16-24 12:47PM
Apr-15-24 04:05PM
Apr-11-24 08:15AM
08:00AM
Apr-10-24 09:00AM
Mar-18-24 06:00AM
Mar-07-24 08:55AM
Mar-05-24 01:51PM
08:05AM
Mar-04-24 09:00AM
Nov-14-23 08:05AM
Nov-01-23 07:45AM
Aug-10-23 08:05AM
Aug-06-23 07:14AM
Aug-04-23 06:40PM
Aug-01-23 10:15PM
Jul-30-23 02:17PM
Jul-18-23 08:05AM
May-11-23 08:05AM
Apr-01-23 08:51AM
Mar-30-23 07:45AM
07:30AM
Mar-29-23 10:13AM
Mar-03-23 06:57PM
Feb-13-23 08:05AM
Jan-09-23 08:05AM
Dec-12-22 09:54AM
07:35AM
Nov-10-22 08:05AM
Nov-09-22 08:05AM
Nov-03-22 09:06AM
Sep-19-22 08:45AM
Aug-11-22 08:05AM
Jun-09-22 08:05AM
May-12-22 08:05AM
Apr-12-22 08:05AM
Mar-29-22 08:05AM
Mar-24-22 08:05AM
Feb-09-22 08:05AM
Jan-21-22 08:05AM
Dec-15-21 08:05AM
Dec-10-21 05:38PM
Nov-23-21 08:05AM
07:59AM
Nov-15-21 08:05AM
Nov-12-21 08:05AM
Nov-11-21 04:45PM
08:30AM
Nov-02-21 09:00AM
Oct-27-21 08:05AM
Oct-26-21 08:05AM
Sep-28-21 08:05AM
Aug-17-21 08:05AM
Aug-12-21 08:05AM
Jul-16-21 08:05AM
Jun-29-21 08:05AM
May-27-21 09:00AM
May-26-21 09:32AM
09:00AM
May-17-21 06:00AM
May-11-21 09:00AM
Apr-09-21 09:00AM
Mar-31-21 08:00AM
Feb-09-21 07:30PM
Jan-11-21 08:00AM
Jan-06-21 12:00PM
Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527, and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded in February 2016 and is headquartered in Seattle, WA.